Worth reading
39Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
19.3
% (year-on-year change in operating profit)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales1,434¥ millionYear on year -2.2%Progress 23.9%
Operating profit192¥ millionYear on year +19.3%Progress 38.4%
Ordinary income189¥ millionYear on year +27.3%Progress 39.4%
Net income attributable to owners of the parent110¥ millionYear on year -49.4%Progress 33.3%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥40.43
Operating Margin13.4%
Financial position at period-end
Total assets10,320¥ million
of which net assets 7,276 ¥ millionEquity ratio 70.5%vs. prior year-end -0.8pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash and cash equivalents at end of period¥2,828,309 thousand
Segment revenue
Techno Products Business1,01771.0%-2.4%
Medical Products Business41629.0%-1.6%
Segment profit
Techno Products Business22286.4%+9.2%
Medical Products Business3513.6%-0.9%
Regional sales
Japan581,27440.5%
Asia589,11541.1%
Europe174,25012.1%
North America66,6454.6%
Latin America and the Caribbean6,2780.4%
Other16,6411.2%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥6,000 million (YoY -0.3%)
Operating profit¥500 million (YoY -18.8%)
Ordinary income¥480 million (YoY -23.8%)
Net income¥330 million (YoY -42.4%)
Revision to Earnings ForecastNo
Annual Dividend Forecast¥35.00 (actual for the fiscal year ended March 2026) → ¥35.00 (forecast for the fiscal year ending March 2027)（0.0%）
Factors Behind Changes in Business Performance
In the Techno Products business, sales of pen tips for writing instruments were sluggish, while sales of pen tips for cosmetics remained firm. In the Medical Products business, the Company conducted proactive promotional activities and focused on sales activities aimed at expanding its market share.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name None
Material subsequent eventsNo applicable matters.
Impairment lossNo applicable matters.
Breakdown of extraordinary income (loss)Extraordinary income No applicable matters. / Extraordinary loss No applicable matters.
Depreciation and amortization¥68,256 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingNo
Issued Shares at Period-End3,092,623
Treasury Shares at Period-End363,268
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | ¥1,434 million (YoY -2.2%) |
| Operating profit | ¥192 million (YoY +19.3%) |
| Ordinary income | ¥189 million (YoY +27.3%) |
| Profit attributable to owners of the parent | ¥110 million (YoY -49.4%) |
| Net income per share | ¥40.43 |
| Operating Margin | 13.4% |
| Equity ratio | End of the current fiscal period 70.5 / End of previous period 71.3 |
| Total assets | ¥10,320 million |
| Net assets | ¥7,276 million |
| Cash and cash equivalents at end of period | ¥2,828,309 thousand |
| Full-year earnings forecast | Net Sales ¥6,000 million (YoY -0.3%) / Operating profit ¥500 million (YoY -18.8%) / Ordinary income ¥480 million (YoY -23.8%) / Net income ¥330 million (YoY -42.4%) |
| Revision to Earnings Forecast | No |
| Annual Dividend Forecast | ¥35.00 (actual for the fiscal year ended March 2026) → ¥35.00 (forecast for the fiscal year ending March 2027)（0.0%） |
| Segment revenue | Techno Products Business ¥1,017 million (YoY -2.4%) / Medical Products Business ¥416 million (YoY -1.6%) |
| Segment profit | Techno Products Business ¥222 million (YoY +9.2%) / Medical Products Business ¥35 million (YoY -0.9%) |
| Regional sales | Japan ¥581,274 thousand / Asia ¥589,115 thousand / Europe ¥174,250 thousand / North America ¥66,645 thousand / Latin America and the Caribbean ¥6,278 thousand / Other ¥16,641 thousand |
| Depreciation and amortization | ¥68,256 thousand |
| Impairment loss | No applicable matters. |
| Breakdown of extraordinary income (loss) | Extraordinary income No applicable matters. / Extraordinary loss No applicable matters. |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | No applicable matters. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | No |
| Issued Shares at Period-End | 3,092,623 |
| Treasury Shares at Period-End | 363,268 |
| Factors Behind Changes in Business Performance | In the Techno Products business, sales of pen tips for writing instruments were sluggish, while sales of pen tips for cosmetics remained firm. In the Medical Products business, the Company conducted proactive promotional activities and focused on sales activities aimed at expanding its market share. |
Items this document does not state (6)
Cash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesPayout ratioShareholder Return PolicyOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.In the Techno Products business, sales of pen tips for writing instruments were sluggish, while sales of pen tips for cosmetics remained firm. In the Medical Products business, the Company conducted proactive promotional activities and focused on sales activities aimed at expanding its market share.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.